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Patients with epithelial ovarian cancer have the best overall survival when maximal surgical effort 
is accomplished. However, despite numerous technological advances, surgery still relies primarily 
on white-light reflectance and the surgeon’s vision. As such, micrometastases are usually missed 
and most patients clinically classified as a complete responder eventually recur and succumb to the 
disease. Our objective is to develop optical enhancers which can aid in the visualization of ovarian 
cancer micrometastasis. To this end we developed a nanoparticle (NP) platform, which is specifically 
targeted to the tumor microenvironment. Targeting is achieved by coating FDA-approved PLGA-PEG 
NP with the peptide sequence RGD, which binds with high affinity to αVβ3 integrins present in both the 
tumor-associated neovasculature and on the surface of ovarian cancer cells. Administration of the NP 
platform carrying fluorescent dyes to mice bearing intraperitoneal ovarian cancer allowed visualization 
of tumor-associated vasculature and its contrast against normal blood vessels. More importantly, we 
demonstrate the visualization of intraperitoneal ovarian cancer micrometastasis as small as 100 μm 
with optimal resolution. Finally, we demonstrate that the fluorescent dye cargo was able to penetrate 
intra-tumorally. Such modality could be used to allow microscopic surgical debulking to assure maximal 
surgical effort.
Ovarian carcinomas are treated by aggressive cytoreductive surgery followed by platinum- and taxane-based 
combination chemotherapy1. This standard of care results in an approximately 80% response rate; however, most 
patients eventually present with recurrent disease within the next five years2. It is in the recurrent setting that 
most patients succumb to the disease as co-presentation of carcinomatosis and chemoresistance limits the value 
of surgery and chemotherapy3. As such, prevention of recurrence has been an objective with the goal of improv-
ing patient survival.
Recurrence is thought to occur due to the presence of undetectable residual disease at the conclusion of 
first-line treatment4–6. Residual disease consists of microscopic chemoresistant cancer cells that survived chemo-
therapy and were missed at surgery. Approaches that have improved survival are those that minimize residual 
disease. Indeed it has been clearly demonstrated that ovarian cancer patients have the best overall survival when 
maximal surgical effort is accomplished7, meaning all tumors visible to the unaided eye of the surgeon have been 
resected. Current studies, however, show that over 50% of patients classified clinically as complete responders 
carry residual disease8,9.
Surgery relies on white-light reflectance and the surgeon’s vision. While identification of large metastases usu-
ally does not pose a challenge, micrometastases are impossible to distinguish intra-operatively. The use of fluores-
cent probes to aid in real-time surgical visualization is a rapidly expanding field10,11 but an even more promising 
approach is the encapsulation of fluorescent probes in nanoparticles (NPs)12,13.
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NPs can encapsulate therapeutic or diagnostic agents and enhance their delivery to specific sites. Coating 
of NPs with polyethylene glycol (PEG) allow avoidance of the host’s reticuloendothelial system and confer the 
“stealth effect”14, which increases the chance of delivery to the targeted site. In addition to improved retention, 
a main advantage in the use of fluorescent NPs is that the NPs allow for conjugation of targeting molecules 
for improved delivery to target sites. In ovarian cancer the value of integrin α vβ 3 in tumor targeting has been 
demonstrated. Integrin α vβ 3 has been shown to be over- expressed in ovarian cancer cell lines and ovarian cancer 
tumors and the role of this integrin in ovarian cancer growth15,16 and metastasis formation17,18 has been described. 
Even more important, is the over-expression of integrin α vβ 3 in ovarian cancer-associated neovasculature but 
minimal expression in normal quiescent blood vessels19,20. These findings provide a strong rationale to determine 
the value of α vβ 3 in specifically targeting the ovarian cancer microenvironment.
Our objective is to develop specific tumor-targeting optical enhancers that can aid in visualization and deline-
ation of intraperitoneal (i.p.) micrometastasis. Towards this goal we utilized a NP-based delivery system to target 
fluorescent probes to the ovarian cancer microenvironment via the tumor-associated neovasculature. Targeting is 
achieved by coating NP composed of FDA approved poly-lactic-co-glycolic acid (PLGA)21 and PEG with the pep-
tide sequence arginine-glycine-aspartate (RGD). RGD binds with high affinity to α Vβ 3 integrins over-expressed 
in tumor-associated neovasculature as well as in ovarian cancer cells. Identification of micrometastasis is achieved 
by visualization of the abnormal vascularity and labeled micrometastasis as small as 100 μ m. Such a platform may 
aid in the performance of microscopic tumor debulking with the goal of minimizing residual disease.
Results
Nanoparticle synthesis and characterization. Our goal is to develop NPs that can deliver diagnostic 
agents to the ovarian cancer microenvironment and visualize micrometastasis and its associated neovascula-
ture. With this objective we synthesized NPs composed of PLGA (5 K)-co-PEG (3.5 K) block copolymers. The 
carboxylic acid group at the end of PEG was used as the conjugation site for the RGD peptide and thus the RGD 
peptides are located on the surface of the NPs (Fig. 1a). We used three different fluorescent dyes - DIR, C6, and 
ICG (designated as DIR-RGD-NP; C6-RGD-NP; ICG-RGD-NP, respectively) and encapsulated them individ-
ually inside the PLGA hydrophobic core of the NPs (Fig. 1a). The sizes of these NPs range from 100 to 200 nm, 
which is confirmed by TEM images (Fig. 1b) and the surface charge is − 5 to − 7 mV. NPs not coated with RGD 
are − 30 ± 5 mV since RGD conjugation takes up the negative charge of the carboxyl functional groups (Fig. 1c). 
The RGD conjugation ratio is 8 ± 5 (mol/mol %) against NP. The encapsulation amount for each fluorescent dye 
are as follows: 120 ± 60 μ g/mg of NP for DIR; 200 ± 45 μ g/mg of NP for C6; and 140 ± 60 μ g/mg of NP for ICG 
Figure 1. Fluorescent probes encapsulated RGD Nanoparticles. (A) Synthesis of RGD-NP composed of 
PLGA-PEG and its self-assembled NP. (B) NPs particle size was determined by DLC (upper panel) and TEM 
(down panel). (C) Surface charges of NP with and without RGD were compared. (D) Encapsulation amount of 
each dye within NP was also determined. (E) The release kinetic of each dye from NP was measured.
www.nature.com/scientificreports/
3Scientific RepoRts | 7:40989 | DOI: 10.1038/srep40989
(Fig. 1D). The release kinetic of DIR and ICG is faster than C6, which may be partly due to the higher hydropho-
bicity of C6 (Fig. 1e) such that the interaction between the hydrophobic core and C6 could delay its release.
Specific staining of tumors and tumor-associated neovasculature with DIR-RGD-NP. We initi-
ated our in vivo studies using the DIR dye. DIR dye is a lipophilic, near infra-red dye with high tissue penetration 
and low autofluorescence22. DIR provides the advantage of being visible to the naked eye in addition to having a 
fluorescent signal. To determine the ability of DIR-RGD-NP to transport DIR to the ovarian tumor microenvi-
ronment we utilized the previously described ovarian cancer xenograft model established using mCherry-labeled 
ovarian cancer cells23,24. The mCherry fluorescence stably expressed by the cancer cells allows the prompt 
co-localization of the DIR signal with the established tumors. Supplementary Figure 1A–C shows the typical 
carcinomatosis formed by these cancer cells and the typical tumor growth progression quantified using mCherry 
ROI fluorescence as surrogate for tumor growth. Analysis of histological sections show morphologic features 
most consistent with a high-grade serous carcinoma, however, p53 immunostaining showed a wild-type staining 
pattern (Supplementary Figure 3). Supplementary Figure 1D shows the expression levels of α Vβ 3 integrins in 
the cancer cells utilized and the resulting i.p. tumor. Using this mouse model, 4 i.p. doses of DIR-RGD-NP were 
given every other day and mice were sacrificed 24 h after the last dose and analyzed post-mortem. Gross inspec-
tion of the abdomen showed intense staining (blue color) of tumor-associated vasculature in mice that received 
four doses of DIR-RGD-NP (corresponding to “lower dose” indicated in Table 1). With this dosing intense dark 
blue staining specifically localized to tumor-associated vasculature (white arrow) can be easily contrasted to the 
deep red normal vasculature (yellow arrow) (Fig. 2A–F). Tumor-associated neovasculature that were positively 
stained by the DIR-RGD-NP delivery system demonstrate the classical tortuous, disorganized, and blunt-ended 
morphology of tumor associated-vessels (Fig. 2F, white arrow) in contrast to the organized and linear morphol-
ogy of normal vasculature (Fig. 2F, yellow arrow). Visualization of the stained tumor associated-vessels allowed 
identification of micrometastasis (Fig. 2F, blue arrow).
Enhanced probe retention and co-localization in vivo when encapsulated in RGD-coated NP. 
To determine if both the NP and the RGD coating is required for the observed tumor staining in Fig. 2 (i.e. mini-
mum component that is required to confer the best sensitivity and specificity), we tested the ability of soluble DIR, 
DIR encapsulated in naked NP (DIR-NP), and DIR-RGD-NP to co-localize with mCherr+ tumors. Fluorescent 
spectral imaging performed on live animals at designated time-points after the 4th dose shows the transient reten-
tion of the DIR probe when it is administered in soluble form (Fig. 3). This agrees with previous data showing the 
rapid clearance of most fluorescent probe from the circulation25. A trivial improvement in the retention of DIR 
signal was observed when it was administered encapsulated in naked NP (DIR-NP) but the best retention was 
observed in mice that received DIR-RGD-NP (Fig. 3). Moreover, in these mice we observed the co-localization 
of the DIR and mCherry signals (yellow foci, white arrows bottom panel) in tumors equal or smaller than 2 mm 
from 30 mins after the last injection up to 24 h later. Co-localization in tumors bigger than 2 mm were however 
limited to the periphery of the tumors and is visualized as a yellow outline that surrounds the red tumor (Fig. 3, 
black arrow bottom panel). These results demonstrate that enhanced in vivo retention and better co-localization 
with big tumors are achieved when DIR is encapsulated in RGD-coated NP.
Best tumor targeting is achieved with encapsulation in RGD-coated NP. Fluorescent spec-
tral imaging and co-localization analysis were also performed ex vivo using dissected small intestines and the 
attached mesentery bearing multiple tumor implants (Fig. 4). Likewise, the best co-localization between DIR 
and mCherry signals were observed in mice that were administered DIR-RGD-NP. Pearson’s correlation coef-
ficient was 0.5 to 0.64 in mice that were administered DIR-RGD-NP compared to 0.2 to 0.35 in mice that were 
administered DIR-NP (p = 0.008) (Supplementary Fig. 2). It should be noted that in mice that were administered 
DIR-RGD-NP, the co-localization was mostly with tumors equal or less than 2 mm (white arrows bottom panel), 
further supporting the platform’s ability to identify micrometastasis. Co-localization analysis could not be per-
formed on mesenteries from control mice and mice that were administered soluble DIR due to lack of DIR signal.
From each of the groups, we also analyzed representative i.p. tumors that range in size from 10 mm to 2 mm. 
Gross inspection of these tumors further show that only in those mice that received DIR-RGD-NP could we 
observe by eye the clear staining and delineation of the tortuous tumor-associated vasculature (Fig. 5A, black 
arrows). Fluorescent spectral imaging performed on these tumors recapitulated the observation that probe reten-
tion within the tumors is best achieved in mice that were administered DIR-RGD-NP (Fig. 5B). Indeed, quanti-
fication of DIR mean fluorescent intensity (MFI) demonstrates that tumors of various sizes obtained from mice 
administered DIR-RGD-NP demonstrate the highest MFI compared to tumors from mice that were adminis-
tered DIR-NP and soluble DIR. Thus in tumors as small as 2 mm, DIR MFI in DIR-RGD-NP group is 696 com-
pared to 430 (p = 0.02) and 274 (p = 0.002) in DIR-NP and soluble DIR groups, respectively (Fig. 5C). MFI in 
Nanoparticle (μg/dose) Dye (μg/dose)
Deep infrared (Dir): lower dose 300 μ g 18 μ g
Deep infrared (Dir): higher dose 600 μ g 36 μ g
Coumarin-6 (C6) 300 μ g 30 μ g
Indocyanine green (ICG) 300 μ g 21 μ g
Table 1.  Nanoparticle and dye concentration per dose.
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tumors from DIR-NP and soluble DIR groups was not significantly different (p = 0.289), suggesting the require-
ment for RGD for enhanced retention. The DIR signal can be seen to penetrate the core of tumors as small as 
2 mm in size when DIR-RGD-NP is administered. As shown in Fig. 5D, quantification of DIR signal in dissected 
tumors that are cut cross-wise shows the best penetration of the DIR probe to the center of the tumor. Taken 
together our results demonstrate that the encapsulation of DIR in RGD-coated NP specifically targets the probe to 
tumor-associated vessels thus resulting in enhanced retention of the DIR signal in the tumor microenvironment 
and better co-localization with micrometastasis. This translates to higher fluorescent intensity within the tumors 
especially those that are less than 2 mm, which are the tumors that may be missed by the naked eye.
Localization and delineation of micrometastasis. To determine the ability of the delivery platform 
to locate and delineate micrometastasis, we analyzed the mice post-mortem under a stereoscopic microscope 
with resolution in the 100 μ m range. Figure 6 shows representative images of mCherry and white light channels. 
Using this approach, we manually counted the following: (1) mCherry+ foci concurrently stained with DIR (true 
positive); (2) mCherry+ foci not stained with DIR (false negative); and (3) mCherry-negative foci stained with 
DIR (false positive). Table 2 summarizes the findings and demonstrate that we were able to identify 82% (± 3%) of 
the micrometastasis in mice administered DIR-RGD-NP compared to 35% (± 42%) and 0% in mice administered 
DIR-NP and soluble DIR, respectively. Correlation of mCherry signal and malignant status was further demon-
strated by histopathological analysis (Supplementary Fig. 3).
Sensitivity and specificity is maintained with one- time dosing. To this point the experiments 
described above utilized 4 doses of the NP platform. For the DIR-RGD-NP group each dose corresponds to 300 μ g 
of NP and 18 μ g of DIR (designated as lower dose in Table 1). Our next objective was to determine the ability of 
a single dose to identify micrometastasis. For this we administered a single i.p. dose of DIR-RGD-NP at two dif-
ferent concentrations (lower dose and higher dose detailed in Table 1) and sacrificed the mice 24 h later. Similar 
to that observed with 4 doses, a single injection of DIR-RGD-NP at the higher dose was able to specifically stain 
micrometastasis. As such micrometastasis smaller than 100 μ m can be easily visualized and delineated with opti-
mal resolution (Fig. 7A, white arrows). Quantification of DIR MFI in dissected tumors 10 mm or less and further 
comparison with background DIR signal from intestines demonstrate signal to background ratio of 2 (± 0.4) 
(Fig. 7Bi). Quantification of DIR signal in tumors that are cut cross-wise shows penetration of the DIR probe to 
the center of the tumor (Fig. 7Bii).
Visualization of micrometastasis using Coumarin-6 and indocyanine green. Our next set of experi-
ment utilized RGD-coated PLGA NPs loaded with Coumarin-6 fluorescent probe (C6-RGD-NP). Coumarin-6 is 
a classical probe used to specifically track the biodistribution of nanoparticles26. Using the described model, mice 
bearing i.p. mCherry+ ovarian cancer were given a single i.p. injection of C6-RGD-NP. Post mortem analysis 
Figure 2. Staining and delineation of tumors and tumor-associated vasculature by DIR-RGD-NP. Upon 
establishment of tumors (ROI~40,000), mice were given four doses of DIR-RGD-NP (‘lower dose” indicated 
in Table 1) given every other day (n = 12). (A–D) Gross tumors appear distinctly stained compared to the 
intestines. Staining is specific to tumor-associated vasculature (white arrow), which can be easily contrasted 
to the normal vasculature (yellow arrow); (E,F) Tumors under the diaphragm are likewise stained; (F) 
Micrometastasis (blue arrow) is visible due to DIR-stained vessels (white arrow) and is contrasted against 
normal vessels (yellow arrow).
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under a fluorescent dissection microscope was performed 2 h later and demonstrated spatial relationship between 
Coumarin-6 and mCherry signals. Coumarin-6 signal was observed as an outline that defines the border of 
mCherry+ tumors (Fig. 8, white arrows).
Finally, we tested the FDA approved fluorescent dye indocyanine green (ICG)27 and utilized the PINPOINT 
endoscopic fluorescence imaging system (Fig. 9A). Tumors less than 2 mm were dissected and their fluorescent 
intensity compared to that of surrounding normal tissue including the heart and liver. Whereas tumors that 
are readily visible to the naked eye demonstrate similar fluorescence levels as the surrounding tissues, small 
micrometastasis that would otherwise be missed demonstrate significantly higher fluorescence compared to the 
surrounding abdomen, heart, and liver (p < 0.001, Fig. 9B). Thus taken together our results demonstrate that 
independent of the fluorescent probe, DIR-RGD-NP provides a sensitive and specific targeting platform for the 
localization of intra-peritoneal micrometastasis.
Discussion
We report the characterization of a NP platform that is able to identify and delineate micrometastasis in an 
intraperitoneal xenograft model of ovarian cancer. Our results demonstrate that encapsulating fluorescent 
dyes in PLGA NPs and coating of NPs with RGD allows for specific targeting and enhanced retention to the 
tumor microenvironment. Consequently, the encapsulated probe is delivered and able to specifically delineate 
intra-peritoneal micrometastasis as small as 100 μ m.
Clinical studies have previously demonstrated that soluble probes are rapidly cleared and are not optimally 
delivered to the tumor microenvironment. In ovarian cancer patients, studies have shown that the use of soluble 
ICG dye intra-operatively leads to a false positive rate of 62%28. Indeed it has been suggested that modalities that 
Figure 3. Enhanced retention and better colocalization in vivo with DIR-RGD-NP. Upon establishment of 
tumors (ROI~40,000), mice were given four doses of soluble DIR, DIR-NP, or DIR-RGD-NP given every other 
day. mCherry (red) and DIR (green) fluorescent images were obtained in live animals at designated time points 
24 h after the 4th dose. Images shown are merged images demonstrating the best colocalization of mCherry and 
DIR signals (yellow) in animals that received DIR-RGD-NP. A representative animal for each delivery system is 
shown; (n = 4 for soluble DIR and DIR-NP; n = 12 for DIR-RGD-NP).
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aim to improve surgical detection of residual disease or micrometastaisis need to be tumor-specific. Asanuma et al. 
recently reported the preclinical potential of β -galactosidase-targeting probes in the detection of micrometastasis 
in ovarian cancer xenografts29. In this current study, we demonstrate a better level of detection using materials 
that are already FDA approved and currently used in the clinic. We demonstrate that we are able to visualize with 
optimal resolution micrometastasis as small as 100 μ m.
A major problem in tumor cell targeting is the lack of specific cellular markers that are unique to the targeted 
tumor. There are a very limited number of proteins that are expressed only by the cancer cells and this number is 
even more restricted for cell surface proteins. On the other hand, there is an expansive set of studies that describe 
the uniqueness of tumor-associated neovasculature, not only in terms of its morphology, but also in terms of the 
cell surface markers that are expressed by the newly formed endothelial cells. Integrin α vβ 3 is either absent or 
weakly expressed in normal endothelial cells but is highly expressed in new and activated endothelial cells espe-
cially in tumor-associated endothelial cells30. Indeed, it has been reported that a considerable number of colon, 
pancreas, lung, and breast carcinoma lesions have vessels that express high levels of α vβ 331–34. In addition, α vβ 3 
has also been demonstrated to be highly expressed in cancer cells including ovarian18. The RGD peptide has been 
demonstrated to function as a specific targeting ligand for α vβ 3 integrins and has been shown to be an optimal 
targeting agent35. We demonstrate in this study that indeed, the RGD-coated NP platform can specifically stain 
tumor-associated neovasculature and as a result can allow the localization and delineation of adjacent microme-
tastasis. Although the use of RGD-coated NPs have been previously described especially as a platform for drug 
Figure 4. Staining of microtumors with DIR-RGD-NP. Fluorescence spectral images from dissected 
intestines and the attached mesentery. Images shown are from mCherry channel (red; left column) and DIR 
channel (green; middle column). The merged images (right column) demonstrate the best colocalization of 
mCherry and DIR signals (white arrow) in animals that received DIR-RGD-NP. A representative animal for 
each delivery system is shown; (n = 4 for soluble DIR and DIR-NP; n = 12 for DIR-RGD-NP).
www.nature.com/scientificreports/
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delivery30 this is the first demonstration of its value in identifying and delineating micrometastasis. We demon-
strate that we are able to visualize, with optimal resolution, micrometastasis as small as 100 μ M.
We show that RGD-coated NPs specifically bind to the tumor-associated vessels and not normal ves-
sels. Independent of the fluorescent probe used the NP system was able to stain tumor-associated vessels and 
demonstrate its tortuous morphology. Based on the distribution of the fluorescence, we speculate that the sig-
nal observed in the tumor microenvironment is mainly coming from the NP bound to tumor endothelial cells. 
However, we can not disregard the possibility of direct binding to cancer cells since ovarian cancer cells also 
express α vβ 3 integrins16,30,36,37.
Once the DIR-RGD-NP binds to tumor-associated vessels the subsequent release of the dye allows diffusion 
into and therefore fluorescent labeling of the cancer cells. This especially occurs in smaller tumors, which pro-
vides an assurance for the identification of micrometastasis that can not be detected by the naked eye.
Both the PLGA NP and the ICG fluorescent probe are re FDA approved and their safety has been well estab-
lished. PLGA is clinically used in a variety of biomedical applications, such as, grafts, sutures, implants, prosthetic 
devices, and surgical sealant films. PLGAs are also being used as microparticles and nanoparticles for drug deliv-
ery. Therefore, the platform described in this study is composed of well-established and FDA-approved compo-
nents, which is a major advantage in its route for diagnostic applications.
The proposed approach may aid in improved microscopic surgical debulking and consequently minimize 
residual disease. In addition, such an approach may improve the visualization of tumor margins and hence reduce 
inadvertent injury to vital structures. Such a modality can assure the best surgical effort and may have significant 
impact on patient survival.
Methods
Nanoparticle synthesis. The procedure for the conjugation of acid-terminated PLGA (MW: 5 K) and 
amine-terminated PEG (MW: 3.5 K) was modified based on previously reported methods38. Acid-terminated 
PLGA (500 mg) and a 10-fold excess of N-hydroxysuccinimide (NHS) and N,N′ -dicyclohexyl carbodiimide 
(DCC) were dissolved in 10 mL of anhydrous dichloromethane (DCM). After stirring at room temperature for 
4 hours, the solution was filtered through a PTFE filter to remove the precipitate. The NHS-activated PLGA was 
Figure 5. Delineation of tumor-associated vasculature with DIR-RGD-NP. (A) Delineation of tumor 
vascularity. White light image of tumors showing the outline of tumor-associated vasculature only when dye 
was administered in RGD-coated nanoparticles; (B) Ex vivo imaging and colocalization of mCherry and DIR 
signals in dissected tumors (from top: 2 mm, 5 mm, and 10 mm in size); (C) Quantification of DIR MFI, data 
shows mean ± SEM, *p < 0.002 compared to soluble DIR and p < 0.0237 compared to DIR-NP;  
(D) Quantification of DIR intensity and penetration in cross-sectioned tumors; a representative animal for each 
delivery system is shown in A, B, and D; (n = 4 for soluble DIR and DIR-NP; n = 12 for DIR-RGD-NP).
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obtained by precipitation in cold ethyl ether. After drying under a vacuum, NHS-activated PLGA was dissolved 
in anhydrous DCM with an equivalent molar ratio of NH2-PEG-COOH and the solution was stirred at room 
temperature. The conjugate was precipitated in cold ethyl ether and dried under a vacuum, yielding a precipi-
tate above 90%. The RGD peptide was conjugated with the carboxylic group of PLGA-PEG-COOH using NHS 
and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC). Using this block co-polymer a fluorescent dye was 
encapsulated into the nanoparticles via dialysis. Specifically, the dye and polymer were dissolved in dimethyl 
sulfoxide (DMSO) and the solution was transferred to a dialysis membrane (MWCO 100,000). The dialysis was 
performed for 24 hours against DI water. After this time, the aqueous particle solution was centrifuged and son-
icated to concentrate the particles.
Nanoparticle characterization. The size of the nanoparticles was determined by dynamic light scattering 
(DLS) using a Zetasizer (Malvern, MA). The sample concentration was maintained at 0.5 mg/mL. The amount 
of dye encapsulation was determined from its absorbance measurement upon dissolving 10 mL of dye NPs into 
990 mL of DMSO, which releases dye into the DMSO solution. Fluorescent dyes used in this study were: (1) 
DIR (1,1′ -dioctadecyl-3,3,3′ ,3′ -Tetramethylindotricarbocyanine Iodine, AAT Bioquest, CA); (2) Coumarin-6 
(C6) (3-2(Benzothiazolyl)-7-(diethylamino)cuomarin, Sigma-Aldrich, MO); and (3) Inodcyanine green 
(ICG) (Akorn, Inc., Lake Forest, IL) and their absorbance wavelengths are 748, 443, and 800 nm, respectively. 
Absorbance was then measured at each wavelength of dye. The encapsulated dye concentration was calculated 
using a pre-measured calibration curve of dye absorbance according to its titrated concentration,. To deter-
mine the dye release profile one milliliter of PBS-dye NPs was prepared in a 1.5 mL microcentrifuge tube with 
moderate shaking. At each time point, the tube was centrifuged to pellet the NPs and the supernatant was col-
lected. The supernatant was diluted 1:100 with DMSO, and its absorbance was measured at each dye wavelength. 
Transmission electron microscopy (Tecnai Osiris 200 kV TEM, FEI, Hillsboro, USA) was performed to elucidate 
Figure 6. Identification of micrometastasis by white light. Stereoscopic images comparing specificity and 
sensitivity of the described nanoparticle platform (full data in Table 2). Squared area and white arrows point to 
micrometastasis. M, mesentery; I, intestines; a representative animal for each delivery system is shown; (n = 4 
for soluble DIR and DIR-NP; n = 12 for DIR-RGD-NP).








Table 2.  Manual counts of detected (mCherry+/DIR+) and missed (mCherry+/DIR-) micrometastasis.
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the morphology of the NPs. A dispersion of the NPs (2 μ L) was placed on a 400-mesh carbon grid followed by 
staining with a phosphotungstic acid solution (1 wt.%). The excess solution was removed and the sample was 
dried at room temperature for the measurement.
Cell lines and culture conditions. The mCherry–labeled ovarian cancer cell line OCSC1-F2 (mCherry+ 
OCSC1-F2) was generated and propagated as previously described23,24. These cells were isolated from ascites from 
a patient diagnosed with a low-grade serous carcinoma arising in a serous borderline tumor. This cell line is not in 
the list of commonly misidentified cell line (www.iclac.org). mCherry fluorescent protein was stably introduced 
using lentivirus. Mycoplasma testing is performed prior to each experiment.
Establishment of ovarian cancer xenograft and administration of fluorescent probes. The Yale 
University Institutional Animal Care and Use Committee approved all of the in vivo studies described and all 
methods were performed in accordance with the relevant guidelines. Intra-peritoneal tumors were established by 
intra-peritoneal (i.p.) injection of 4 × 106 mCherry+ OCSC1-F2 cells in 6–8 weeks female athymic nude mice. 
I.p. tumor growth was monitored q3d by live imaging using In Vivo FX PRO (Bruker Corp., Billerica, MA) and 
quantified using the mCherry fluorescence region of interest (ROI) area as a surrogate for tumor growth. Animals 
were randomized into groups and the described probes were administered i.p. when the mCherry ROI area was 
between the range of 40,000 and 50,000. DIR dye in the following delivery systems were administered: (1) soluble; 
(2) encapsulated in naked NP; (3) encapsulated in RGD-coated NP. C6 and ICG were also encapsulated in 
RGD-coated NP and administered similarly. The concentration of nanoparticle and concentration of each dye are 
listed in Table 1. All animals were included in the analysis.
Fluorescence spectral imaging, quantification, and colocalization analysis. Live in vivo x-ray 
and fluorescence images were obtained using In Vivo MS FX PRO (Bruker, Inc., Billerica, MA) in mice that were 
administered 2% isoflurane. Quantitative analysis of the optical signal capture was performed using Bruker MI 
Software. Fluorescence filters were as follows: (1) mCherry excitation = 550 and emission = 635; (2) DIR excita-
tion = 760 and emission = 700; and (3) Coumarin 6 excitation = 450 and emission = 700. Fluorescence intensity 
Figure 7. Specificity of detection is maintained with one time dosing of DIR-RGD-NP. (A) Upon 
establishment of tumors (ROI~40,000), mice were given a single dose of DIR-RGD-NP (“higher dose” indicated 
in Table 1; n = 4). Stereoscopic images show detection of micrometastasis by white light. White arrows point to 
micrometastasis. M, mesentery; I, instestines. (B) i, Ex vivo imaging and colocalization of mCherry and DIR 
signals in dissected tumors; ii, quantification of DIR intensity and penetration in cross-sectioned tumors.
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for each of the probes was determined and reported as mean fluorescent intensity (MFI). Images were overlaid 
and analyzed for colocalization (Pearsons’s correlation coefficient) using ImageJ software (v 2.0). For all analysis, 
the investigators were not blinded to the group allocation.
PINPOINT endoscopic system. The endoscopic PINPOINT system was operated at 5 cm working dis-
tance from the animal surface, which allows the animal’s entire abdomen to be viewed in a single field of view. 
Semiquantitative comparison of the distribution of ICG NPs was based on fluorescence intensity measured from 
different areas of the animal abdomen using ImageJ software.
Figure 8. Biodistribution of C6-RGD-NP in the tumor microenvironment. Upon establishment of tumors 
(ROI~40,000), mice were given a single dose Cu6-RGD-NP and sacrificed after 2 h (n = 4). Fluorescence 
imaging demonstrates the spatial relationship between the DIR and mCherry signals; scale bar = 180 μ m.
Figure 9. Visualization of micrometastasis using the ICG probe and the PINPOINT system.  
(A) Images from the PINPOINT system demonstrating the visualization of tumor-associated vasculature and 
micrometastasis (arrows); (B) quantification of ICG intensity showing most intense staining in tumors less than 
5 mm compared to the rest of the abdomen, data shows mean ± SEM,*p < 0.0001 compared to abdomen, heart, 
and liver (n = 4).
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Statistical analysis. Data were graphed and analyzed using GraphPad Prism. Significance was calculated 
using one-way ANOVA or two-way ANOVA with Tukey’s correction for multiple comparisons, and p < 0.05 was 
considered significant.
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